Press release from Companies
Published: 2025-08-05 10:01:00
Med-tech company PolarCool AB (publ.) has extended its collaboration with French rugby giant Stade Français Paris. The new two-year agreement will run through the end of the 2027 season.
France, where rugby holds a prominent place in the national sports landscape, remains a key market for PolarCool. In 2021, Stade Français Paris became the first professional rugby club to integrate PolarCap® into its concussion management protocol. Over the past four seasons, the club has successfully utilized PolarCap® with consistently positive outcomes.
Since then, PolarCool has expanded its footprint in French rugby, partnering with additional top-tier clubs including Racing 92, Aviron Bayonnais, and US Oyonnax.
PolarCool CEO Erik Andersson comments;
-Stade Français Paris, a top-tier club, has used PolarCap® with positive outcomes for four years. I’m proud that the club has chosen to extend our collaboration once again. This agreement validates the value of our technology and its efficacy in treating concussions, while also reinforcing our position in a key market. We look forward to continuing our successful partnership.
PolarCool AB develops PolarCap®, a medical device designed to mitigate the effects of concussions. The company primarily serves sports clubs in high-risk sports such as ice hockey, rugby, football, and handball.
While the financial impact of individual agreements is limited, this contract is of strategic significance.
For more information
Erik Andersson – CEO PolarCool AB (publ.)
+46 - 738 60 57 00
E-mail: erik.andersson@polarcool.se
About PolarCool AB (publ.)
PolarCool AB (publ.) is a Swedish medical technology company focused on developing and marketing products in the sports medicine field. Its primary product, PolarCap®, is designed to reduce the impact of concussion through targeted brain cooling. PolarCool works with professional teams across Europe in rugby, football, and ice hockey and it shares are listed on Spotlight Stock Market.